{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023478","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.804964+00:00","generated_at":"2026-05-22T04:18:41.433387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025","bullets":["Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.","R&D expenses $6.1M, up from $3.7M, driven by VYN202 and repibresib trials.","Phase 1b psoriasis trial of VYN202 placed on clinical hold after testicular toxicity in dogs.","Repibresib gel Phase 2b vitiligo top-line results expected mid-2025; fully enrolled.","Revenue $0.2M from LEO Pharma royalty; cash runway into 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023478","json":"https://secwatch.observer/filing/0001628280-25-023478.json","markdown":"https://secwatch.observer/filing/0001628280-25-023478.md","text":"https://secwatch.observer/filing/0001628280-25-023478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/0001628280-25-023478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/mnlo-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:18:41.433387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}